Jump to ContentJump to Main Navigation
Show Summary Details

Radiology and Oncology

The Journal of Association of Radiology and Oncology

4 Issues per year


IMPACT FACTOR 2015: 1.736

SCImago Journal Rank (SJR) 2015: 0.631
Source Normalized Impact per Paper (SNIP) 2015: 0.968
Impact per Publication (IPP) 2015: 1.796

Open Access
Online
ISSN
1581-3207
See all formats and pricing
Volume 46, Issue 3 (Sep 2012)

Issues

Intensity modulated radiation therapy (IMRT) for the treatment of unicentric Castlemans disease: a case report and review of the use of radiotherapy in the literature

Chance Matthiesen
  • Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
/ Rajeev Ramgopol
  • Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
/ Jonathan Seavey
  • Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
/ Salahuddin Ahmad
  • Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
/ Terence Herman
  • Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Published Online: 2012-01-02 | DOI: https://doi.org/10.2478/v10019-012-0008-0

Intensity modulated radiation therapy (IMRT) for the treatment of unicentric Castlemans disease: a case report and review of the use of radiotherapy in the literature

Background. Surgical resection is considered standard therapy for cases of resectable unicentric Castleman's disease (UCD). Unresectable cases of UCD do not have a consensus regarding the optimal treatment approach, but have utilized steroids, observation, chemotherapy, and radiotherapy. Here we discuss a patient presentation of UCD treated with an advanced radiotherapy technique, IMRT.

Case report. A 47 year old female was found to have an intra-thoracic posterior UCD and was determined not to be a good surgical candidate. She was referred for radiotherapy and was treated using IMRT to a total dose of 4320 cGy in 180 cGy fractions including a scheduled 10 day break. Following the break, the patient's treatment was replanned at which the initial treatment volume was reduced by 50.9% for the duration of the treatment course. Radiation Therapy Oncology Group (RTOG) grade III pneumonitis developed which was managed medically. Neither disease progression nor late effects have occurred.

Conclusions. The use of IMRT and planned treatment break was successful in the treatment of a case of UCD, and should be considered for other unresectable cases.

Keywords: Castleman's disease; IMRT

  • Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956; 9: 822-30. [PubMed]

  • Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978; 69: 86-90. [PubMed]

  • Soulier J, Grollet L, Oksenhendler E, Miclea JM, Cacoub P, Baruchel A, et al. Molecular analysis of clonality in Castleman's disease. Blood 1995; 86: 1131-8.

  • Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86: 1276-80.

  • Gessain A, Sudaka A, Brière J, Fouchard N, Nicola MA, Rio B, et al. Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman's disease: is there any relevant association in non-human immunodeficiency virus-infected patients? Blood 1996; 87: 414-6.

  • Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998; 128: 657-62. [PubMed]

  • Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005; 129: 3-17. [PubMed] [Crossref]

  • Seco JL, Velasco F, Manuel JS, Serrano SR, Tomas L, Velasco A. Retroperitoneal Castleman's disease. Surgery 1992; 112: 850-5. [PubMed]

  • McCarty MJ, Vukelja SJ, Banks PM, Weiss RB. Angiofollicular lymph node hyperplasia (Castleman's disease). Cancer Treat Rev 1995; 21: 291-310.

  • Shahidi H, Myers JL, Kvale PA. Castleman's disease. Mayo Clin Proc 1995; 70: 969-77.

  • Neuhof D, Debus J. Outcome and late complications of radiotherapy in patients with unicentric Castleman disease. Acta Oncol 2006; 45: 1126-31. [PubMed]

  • Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001; 92: 670-6. [PubMed]

  • Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999; 85: 706-17.

  • de Vries IA, van Acht MM, Demeyere TB, Lybeert ML, de Zoete JP, Nieuwenhuijzen GA. Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature. Radiat Oncol 2010; 5: 7. [Web of Science]

  • Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol 1993; 20: 636-47. [PubMed]

  • Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972; 29: 670-83. [Crossref] [PubMed]

  • Ye B, Gao SG, Li W, Yang LH, Zhao SH, Ma K, et al. A retrospective study of unicentric and multicentric Castleman's disease: a report of 52 patients. Med Oncol 2010; 27: 1171-8. [Web of Science]

  • Lin CY, Chang YL. Castleman's disease in the head and neck region: Meta-analysis of reported cases in Taiwan and literature review. J Formos Med Assoc 2010; 109: 913-20.

  • Paumier A, Ghalibafian M, Beaudre A, Ferreira I, Pichenot C, Messai T, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011; 80: 199-205. [PubMed]

  • Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: A dosimetric study. Int J Radiat Oncol Biol Phys 2011; 81: 1336-42. [PubMed]

  • Lievens Y, Nulens A, Gaber MA, Defraene G, De Wever W, Stroobants S, et al. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study. Int J Radiat Oncol Biol Phys 2011; 80: 306-13. [PubMed]

  • Banu A, Enis O, Kaan G, Gungor G. Intensity modulated radiotherapy (IMRT) in bilateral retinoblastoma. Radiol Oncol 2010; 44: 194-8. [Web of Science]

  • Bailey DW, Lalith K; Podgorsak MB. A fully electronic intensity-modulated radiation therapy quality assurance (IMRT) process implemented in a network comprised of independent treatment planning, record and verify, and delivery systems. Radiol Oncol 2010; 44: 124-30. [Web of Science]

  • Śladowska A, Hetnał M, Dymek P, Kabat D, Kisielewicz K, Wawrzak M, et al. Application of IMRT in adjuvant treatment of soft tissue sarcomas of the thigh - preliminary results. Reports of Practical Oncology and Radiotherapy 2011; 16: 110-4.

  • Weisenburger DD, DeGowin RL, Gibson P, Armitage JO. Remission of giant lymph node hyperplasia with anemia after radiotherapy. Cancer 1979; 44: 457-62. [PubMed]

  • Nordstrom DG, Tewfik HH, Latourette HB. Plasma cell giant lymph node hyperplasia responding to radiation therapy. AJR Am J Roentgenol 1978; 130: 169-71. [PubMed] [Crossref]

  • Marti S, Pahissa A, Guardia J, Moragas A, Bacardi R. Multicentric giant follicular lymph node hyperplasia. Favorable response to radiotherapy. Cancer 1983; 51: 808-10. [PubMed]

  • Veldhuis GJ, van der Leest AH, de Wolf JT, de Vries EG, Vellenga E. A case of localized Castleman's disease with systemic involvement: treatment and pathogenetic aspects. Ann Hematol 1996; 73: 47-50. [Crossref]

  • Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330: 602-5.

  • Li X, Wang X, Li Y, Zhang X. A 4D IMRT planning method using deformable image registration to improve normal tissue sparing with contemporary delivery techniques. Radiat Oncol 2011; 6: 83. [Web of Science] [Crossref]

  • Chapet O, Fraass BA, Ten Haken RK. Multiple fields may offer better esophagus sparing without increased probability of lung toxicity in optimized IMRT of lung tumors. Int J Radiat Oncol Biol Phys 2006; 65: 255-65.

  • Suciu D. Cellular death by apoptosis in some radiosensitive and radioresistant mammalian tissues. J Theor Biol 1983; 105: 391-401. [PubMed]

About the article


Published Online: 2012-01-02

Published in Print: 2012-09-01


Citation Information: Radiology and Oncology, ISSN (Online) 1581-3207, ISSN (Print) 1318-2099, DOI: https://doi.org/10.2478/v10019-012-0008-0. Export Citation

This content is open access.

Comments (0)

Please log in or register to comment.
Log in